Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825500 · ClinicalTrials.gov registry record · Phase 2
Staccato Loxapine in Migraine (Out Patient)
A Phase 2 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT00825500: Completed Phase 2 study, sponsored by Alexza Pharmaceuticals.
NCT00825500 is a Phase 2 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 366 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (175% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00825500, a Phase 2 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
Assess the safety and efficacy of Staccato Loxapine in patients with moderate to severe migraine headache with or without aura in an outpatient setting.
Primary Outcome
Pain-Relief=pretreatment pain rating of 2 (moderate) or 3 (severe) and a rating of 0 (none) or 1 (mild) at the designated assessment time
Interventions
- DRUG Inhaled Placebo
- DRUG Inhaled Loxapine 1.25 mg
- DRUG Inhaled Loxapine 2.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00825500 record still lists
NCT00825500 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (175% higher).
The record links to 0 conditions, and to 3 interventions - of which Inhaled Placebo is the first listed.
NCT00825500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00825500 about?
NCT00825500 is a clinical study titled "Staccato Loxapine in Migraine (Out Patient)". Assess the safety and efficacy of Staccato Loxapine in patients with moderate to severe migraine headache with or without aura in an outpatient setting.
What is the current status of trial NCT00825500?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2009-01. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00825500?
The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled Loxapine 1.25 mg (DRUG), Inhaled Loxapine 2.5 mg (DRUG).
Who is sponsoring clinical trial NCT00825500?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00825500's enrollment target sits among peer trials
366 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia